Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Merck Recalls MMR Vaccine

June 22, 2012 10:21 am | News | Comments

Merck & Co. is recalling 39,000 doses of a vaccine against measles, mumps, and rubella because it was shipped before the company finished an internal approval process.

TOPICS:

FDA Denies Xarelto Expansion

June 22, 2012 10:17 am | News | Comments

Federal regulators have denied Johnson & Johnson's request to expand approval of Xarelto for a new use preventing life-threatening blood clots in high-risk patients.

TOPICS:

Oligonucleotide Synthesis

June 21, 2012 12:01 pm | Product Releases | Comments

Link Technologies Ltd has launched two modified phosphoramidite ranges to complement its existing extensive portfolio of products to support oligonucleotide synthesis.

TOPICS:
Advertisement

Size Exclusion Chromatography Column

June 21, 2012 11:56 am | Drug Discovery & Development | Product Releases | Comments

Phenomenex Inc. introduces Yarra—a family of aqueous size exclusion chromatography (SEC) columns for biomolecule analysis.

TOPICS:

UHPLC System

June 21, 2012 11:50 am | Drug Discovery & Development | Product Releases | Comments

Thermo Fisher Scientific Inc. has introduced the UltiMate 3000 XRS UHPLC system, offering advanced solvent delivery and sample handling with a range of detector options.

TOPICS:

New Ways to Target Prostate Cancer

June 21, 2012 11:40 am | News | Comments

New classes of drugs target the androgens that prostate cancer thrive off in novel ways, providing alternatives to traditional methods that often carry high side effects.

TOPICS:

Molecule May Jumpstart Heart Repair

June 21, 2012 11:30 am | News | Comments

Researchers have discovered that a single protein may hold the key to turning cardiac stem cells into blood vessels or muscle tissue.

TOPICS:

UW Enrolling for Leukemia Study

June 21, 2012 11:22 am | News | Comments

The University of Washington has begun enrolling patients in a Phase 2 study testing Cell Therapeutics' tosedostat in elderly patients with acute myeloid leukemia.

TOPICS:
Advertisement

Huntington's Trial Completes Enrollment

June 21, 2012 11:16 am | News | Comments

Raptor Pharmaceutical Corp. has finished enrollment for its Phase 2/3 clinical trial of RP103 for the potential treatment of Huntington's disease.

TOPICS:

Population Genetics Collaborating with Oxford

June 21, 2012 11:10 am | News | Comments

Two research groups are using Population Genetics Technologies to enable studies on gene variants associated with myocardial infarction, diabetes, and metabolic disease.

TOPICS:

AstraZeneca Buys Ardea for $1.26B

June 21, 2012 11:00 am | News | Comments

AstraZeneca PLC said that it completed its $1.26 billion acquisition of gout drug developer Ardea Biosciences Inc.

TOPICS:

Strong Data Boosts Idenix Treatment

June 21, 2012 10:56 am | News | Comments

Hepatitis C drug developer Idenix Pharmaceuticals Inc. has reported promising results from a mid-stage study of a potential treatment.

TOPICS:

No New Trial in Risperdal Case

June 21, 2012 10:53 am | News | Comments

A judge has denied a request for a new trial after he fined Johnson & Johnson and a subsidiary $1.2 billion for downplaying and concealing risks associated with Risperdal.

TOPICS:

Panel in Favor of Carfilzomib

June 21, 2012 10:48 am | News | Comments

A panel of cancer specialists endorsed a potential blood cancer treatment from Ligand Pharmaceuticals' development partner, Onyx Pharmaceuticals.

TOPICS:

EMD Millipore Launches Provantage Solutions

June 20, 2012 12:09 pm | News | Comments

EMD Millipore has launched Provantage Solutions, process development, manufacturing consulting, and implementation services, provided by EMD Millipore scientists.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading